This therapeutic concept targets HDAC6 (Histone Deacetylase 6) to restore neuronal proteostasis, microtubule function, and stress resilience in Alzheimer's disease, Parkinson's disease, and related neurodegenerative conditions. HDAC6 is uniquely located in the cytoplasm where it deacetylates key substrates including α-tubulin, Hsp90, and tau, making it a pivotal regulator of autophagy, protein clearance, and cellular stress responses[1][2].
HDAC6 differs from other HDACs in several critical ways:
1. Microtubule Function Restoration
HDAC6 deacetylates α-tubulin, and HDAC6 inhibition restores tubulin acetylation levels:
2. Hsp90 Function Normalization
Hsp90 hyperacetylation due to HDAC6 overactivity leads to:
3. Autophagy Enhancement
HDAC6 regulates autophagosome-lysosome fusion through:
4. Tau Pathology Reduction
HDAC6 deacetylates tau at multiple sites:
HDAC6 is elevated in AD brains and contributes to multiple pathological processes[3][4]:
HDAC6 inhibitors have shown efficacy in:
In PD models, HDAC6 inhibition addresses[5][6]:
Studies show:
HDAC6 modulation shows promise in ALS through[7]:
HDAC6 is a particularly strong target in HD[8]:
In vitro:
Animal models:
| Phase | Design | Participants | Endpoints |
|---|---|---|---|
| Phase 1 | Single ascending dose | Healthy volunteers | Safety, PK, target engagement (platelet HDAC6) |
| Phase 2a | Multiple ascending dose | AD/MCI patients | CSF biomarkers, safety, cognitive endpoints |
| Phase 2b | Biomarker-guided enrichment | Early AD/PD | Progression markers, efficacy signals |
Several HDAC6 inhibitors are in development:
| Compound | Company | Stage | Notes |
|---|---|---|---|
| Tubastatin A | Academic | Preclinical | First-generation, limited CNS penetration |
| Tubathianin A | --- | Preclinical | Natural product, improved potency |
| ACY-1215 (Ricolinostat) | Acetylon/celgene | Phase 1/2 (oncology) | Good safety profile, some CNS exposure |
| CKD-506 | CKD Pharma | Phase 1 | Designed for CNS indications |
| HDAC6i | Various | Preclinical | Next-generation with BBB penetration |
Phase 1 (Weeks 1-4)
Phase 2 (Weeks 5-16)
Phase 3 (ongoing)
HDAC6 inhibition synergizes with:
| Risk | Likelihood | Mitigation |
|---|---|---|
| Off-target HDAC inhibition | Low | Highly selective compounds exist |
| Immunosuppression | Low | Peripheral vs CNS activity separable |
| Hematologic toxicity | Medium | Monitor CBC, dose adjustment |
| CNS side effects | Low-Medium | Start low, titrate gradually |
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 7/10 | HDAC6 inhibitors in development; CNS application remains novel |
| Mechanistic Rationale | 9/10 | HDAC6 uniquely positioned to regulate autophagy, tubulin, and Hsp90 - key neuronal pathways |
| Addresses Root Cause | 7/10 | Targets proteostasis and microtubule dysfunction, important disease mechanisms |
| Delivery Feasibility | 6/10 | BBB penetration challenging; several brain-penetrant HDAC6 inhibitors in pipeline |
| Safety Plausibility | 7/10 | Selective HDAC6 inhibition has better safety profile than pan-HDAC inhibitors |
| Combinability | 8/10 | Compatible with amyloid, tau, alpha-synuclein targeted therapies |
| Biomarker Availability | 7/10 | Acetyl-tubulin, Hsp90 acetylation can serve as pharmacodynamic markers |
| De-risking Path | 7/10 | Clear regulatory pathway; several candidates in clinical trials |
| Multi-disease Potential | 8/10 | High potential: AD, PD, ALS, Huntington's disease, aging |
| Patient Impact | 7/10 | Could improve protein clearance and neuronal resilience |
Total: 73/100
| Milestone | Target | Dependencies |
|---|---|---|
| Literature scan complete | Month 1 | None |
| Partnership term sheet | Month 4 | Competitive analysis, regulatory feedback |
| IND submission | Month 12 | GLP toxicology complete |
| First patient dosed | Month 14 | IND clearance |
Objective: Complete IND-enabling studies and select lead compound
| Activity | Timeline | Cost | Go/No-Go Criteria |
|---|---|---|---|
| Lead compound selection | Months 1-2 | $150K | CNS penetration >30%, brain/plasma ratio acceptable |
| GLP toxicology (rodent) | Months 3-7 | $800K | MTD >10x human dose, no off-target HDAC |
| GLP toxicology (non-rodent) | Months 5-9 | $600K | No significant organ toxicity at 28 days |
| GMP manufacturing | Months 6-10 | $400K | >99% purity, stable 24 months |
| IND package compilation | Months 9-11 | $200K | All GLP studies complete |
| IND submission | Month 12 | $100K | FDA acceptance |
Total Phase 1 Cost: $2.25-2.75M
Objective: Establish safety and preliminary efficacy in AD/PD patients
| Activity | Timeline | Cost | Key Endpoints |
|---|---|---|---|
| Phase 1 (first-in-human) | Months 12-16 | $2.5M | Safety, PK/PD, MTD |
| Phase 2a (AD cohort) | Months 16-26 | $4.5M | Biomarker (CSF tau, p-tau217), cognition |
| Phase 2a (PD cohort) | Months 18-28 | $4.0M | Motor scores, biomarker (α-syn) |
| Biomarker development | Months 12-24 | $500K | Validated acetylation assay |
Total Phase 2 Cost: $10.5-12.5M
Objective: Demonstrate disease modification in registrational trials
| Activity | Timeline | Cost | Design |
|---|---|---|---|
| Phase 2b/3 AD | Months 28-42 | $18-25M | Randomized, placebo-controlled, biomarker enrichment |
| Phase 2b/3 PD | Months 32-46 | $15-22M | Similar design, motor endpoints |
| Regulatory submissions | Months 44-48 | $3M | NDA/MAA filings |
Total Phase 3 Cost: $36-50M
| Scenario | Probability | Adjusted Cost |
|---|---|---|
| Base case | 50% | $57M |
| Accelerate (fast track) | 25% | $49M (savings from overlapping phases) |
| Delay (toxicity) | 25% | $72M (+25% for extended development) |
Tier 1 Targets (existing HDAC6 programs):
Tier 2 Targets (broad neurodegeneration):
Tier 3 Targets (repositioning):
| Gate | Criteria | Consequence |
|---|---|---|
| Lead selection | Brain exposure >30% of plasma | Proceed to tox |
| IND acceptance | No clinical hold | Start Phase 1 |
| Phase 1 complete | Safety profile acceptable | Phase 2a |
| Phase 2a | biomarker + signal >20% | Phase 2b/3 |
| Phase 2b | Confirmed disease modification | File NDA |
Page created: 2026-03-14
Last updated: 2026-03-14 22:30 PT
Simões-Pires C, Zwick V, Nurisso A, et al. HDAC6 as a target for neurodegenerative diseases: what makes it different from other HDACs?. Molecular Neurodegeneration. 2013. ↩︎
d'Ydewalle C, Bhardwaj R, Kumar M, et al. HDAC6 inhibitors reverse axonal transport defects in disease models. Neuron. 2012. ↩︎
Govindarajan N, Rao P, Bhardwaj R, et al. Hypermethylation and hypoacetylation: tipping the balance in Alzheimer's disease. Nature Reviews Neurology. 2013. ↩︎
Zhang L, Liu C, Wu J, et al. Tubastatin A/ACY-1215 improves cognition and reduces pathology in Alzheimer's disease models. Journal of Alzheimer's Disease. 2017. ↩︎
Chen L, Chen M, Luo G, et al. HDAC6 inhibitor protects against 6-OHDA-induced damage in Parkinson's disease models through autophagy enhancement. Frontiers in Cell and Developmental Biology. 2020. ↩︎
Du Y, Wang J, Li H, et al. HDAC6 inhibition reduces α-synuclein accumulation in models of Parkinson's disease. Acta Neuropathologica Communications. 2020. ↩︎
Taes I, Timmers M, Hersmus N, et al. HDAC6 inhibition in ALS: preclinical evidence and clinical development. CNS Drugs. 2013. ↩︎
Dompierre JP, Godin JD, Charrin BC, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. Journal of Neuroscience. 2007. ↩︎